Cognition Therapeutics, Inc.
CGTX
$0.3529
$0.033510.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.57M | 3.07M | 3.10M | 3.55M | 3.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.72M | 14.46M | 14.68M | 14.10M | 15.19M |
| Operating Income | -10.72M | -14.46M | -14.68M | -14.10M | -15.19M |
| Income Before Tax | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M |
| EBIT | -10.72M | -14.46M | -14.68M | -14.10M | -15.19M |
| EBITDA | -10.70M | -14.44M | -14.65M | -14.08M | -15.16M |
| EPS Basic | -0.18 | -0.25 | -0.18 | -0.27 | -0.26 |
| Normalized Basic EPS | -0.11 | -0.15 | -0.11 | -0.34 | -0.16 |
| EPS Diluted | -0.18 | -0.25 | -0.18 | -0.27 | -0.27 |
| Normalized Diluted EPS | -0.11 | -0.15 | -0.11 | -0.34 | -0.16 |
| Average Basic Shares Outstanding | 44.68M | 40.42M | 40.06M | 33.74M | 31.03M |
| Average Diluted Shares Outstanding | 44.68M | 40.42M | 40.06M | 33.74M | 31.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
